Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112021168 | 11202116 | 8 | F | 20140620 | 20160824 | 20150619 | 20160830 | EXP | PHHY2014CA079720 | NOVARTIS | 58.49 | YR | F | Y | 0.00000 | 20160830 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112021168 | 11202116 | 1 | PS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | 100 UG, ONCE/SINGLE (TEST DOSE) | 19667 | 100 | UG | 1X | |||||||
| 112021168 | 11202116 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO (EVERY 4 WEEKS) | 0 | 30 | MG | /month | |||||||
| 112021168 | 11202116 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, QMO (EVERY 28 DAYS) | 0 | 60 | MG | /month | |||||||
| 112021168 | 11202116 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, QMO (EVERY 28 DAYS) | 0 | 60 | MG | /month |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 112021168 | 11202116 | 1 | Neuroendocrine carcinoma |
| 112021168 | 11202116 | 2 | Neuroendocrine carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 112021168 | 11202116 | HO |
| 112021168 | 11202116 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 112021168 | 11202116 | Abdominal pain | |
| 112021168 | 11202116 | Blood pressure increased | |
| 112021168 | 11202116 | Blood pressure systolic increased | |
| 112021168 | 11202116 | Cholecystitis | |
| 112021168 | 11202116 | Cholelithiasis | |
| 112021168 | 11202116 | Dysphonia | |
| 112021168 | 11202116 | Gallbladder oedema | |
| 112021168 | 11202116 | Inflammation | |
| 112021168 | 11202116 | Injection site haemorrhage | |
| 112021168 | 11202116 | Injection site pain | |
| 112021168 | 11202116 | Intestinal obstruction | |
| 112021168 | 11202116 | Lymphadenopathy | |
| 112021168 | 11202116 | Malignant neoplasm progression | |
| 112021168 | 11202116 | Mitral valve disease | |
| 112021168 | 11202116 | Neuroendocrine carcinoma | |
| 112021168 | 11202116 | Pyelonephritis | |
| 112021168 | 11202116 | Tenderness | |
| 112021168 | 11202116 | Tricuspid valve disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 112021168 | 11202116 | 1 | 20140620 | 20140620 | 0 | |
| 112021168 | 11202116 | 2 | 20140702 | 0 | ||
| 112021168 | 11202116 | 3 | 20160113 | 0 | ||
| 112021168 | 11202116 | 4 | 20160210 | 0 |